Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMercy Medical Center
About this trial
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Eligibility criteria
Qualifiers
None
Disqualifiers
Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
Those who had previous exposure to hepatitis B.
Post liver transplant patients.
Less than 18 years old.
Trial design
Treatments tested in this trial
- Heplisav-B Injectable Product, 2-dose regimen
- Heplisav-B Injectable Product, 3-dose regimen
Treatment groups
200 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov